Intracellular Delivery of Nanoparticles and DNAs by IR9 Cell-penetrating Peptides

Betty R. Liu¹, Ji-Sing Liou¹, Yue-Wern Huang², Robert S. Aronstam², Han-Jung Lee¹*¹

¹ Department of Natural Resources and Environmental Studies, National Dong Hwa University, Hualien, Taiwan, ² Department of Biological Sciences, Missouri University of Science and Technology, Rolla, Missouri, United States of America

Abstract

Cell-penetrating peptides (CPPs) comprised of basic amino residues are able to cross cytoplasmic membranes and are able to deliver biologically active molecules inside cells. However, CPP/cargo entrapment in endosomes limits biomedical utility as cargoes are destroyed in the acidic environment. In this study, we demonstrate protein transduction of a novel CPP comprised of an INF7 fusion peptide and nona-arginine (designated IR9). IR9 noncovalently interacts with quantum dots (QDs) and DNAs to form stable IR9/QD and IR9/DNA complexes which are capable of entering human A549 cells. Zeta-potentials were a better predictor of transduction efficiency than gel shift analysis, emphasizing the importance of electrostatic interactions of CPP/cargo complexes with plasma membranes. Mechanistic studies revealed that IR9, IR9/QD and IR9/DNA complexes may enter cells by endocytosis. Further, IR9, IR9/QD and IR9/DNA complexes were not cytotoxic at concentrations below 30, 5 and 20.1 μM, respectively. Without labor intensive production of fusion proteins from prokaryotes, these results indicate that IR9 could be a safe carrier of genes and drugs in biomedical applications.

Introduction

The cell membrane is a permeable barrier that protects living cells from the extracellular environment by controlling the movement of materials into and out of cells. The cytoplasmic membrane mediates a wide range of essential processes, including environmental sensing, nutrient uptake, cellular morphogenesis, secretion and cell wall biogenesis [1]. The importance of the plasma membrane is reflected by the fact that most pharmaceutical drugs target plasma membrane components [2]. Transport of exogenous molecules across this barrier is complex and is influenced by phospholipid, glycolipid, cholesterol and protein composition. Membrane permeability depends on specific membrane transporters as well as the size and polarity of molecules of interest. In the absence of specific transporters, the membrane only allows the movement of small hydrophobic molecules into the cell [3]. Large hydrophilic drugs and biological macromolecules, including DNAs, RNAs and proteins, do not cross cell membranes freely.

Cell-penetrating peptides (CPPs, also known as protein transduction domains) are a group of short peptides capable of traversing cell membrane and delivering a variety of cargoes into living cells [3–8]. They were originally derived from the viral transactivation of transcription (Tat) protein that is capable of crossing cell membranes [9,10]. A basic amino acid-rich region of the truncated Tat protein was identified as the domain responsible for penetrating cell membranes and accumulating in cell nuclei [11]. During the last 15 years, more than 100 varieties of CPPs have been reported [12], and 843 CPPs are catalogued on the CPPSite (http://crdd.osdd.net/raghava/cppsite/) [13]. The essential feature of CPPs is the ability to transport other molecules into cells. CPPs include amphipathic, hydrophobic and cationic peptides [14]. CPPs can be classified into three major families: protein-derived, synthetic and chimeric [12]. For instance, Tat and penetratin, two of the first CPPs discovered, are protein-derived [4]. Nona-arginine (R9) and the model amphipathic peptide do not have any natural parent proteins and belong to the synthetic family. Members of the chimeric family incorporate various functional domains of natural proteins, such as Pep-1 and transportan [12]. Each family can be divided into several subgroups based on their origin or sequence characteristics.

In recent years, CPPs have been exploited to deliver biologically active molecules into cells and are one of the most promising tools in therapeutics [15]. Recently, more than 20 clinical trials are using CPPs to deliver macromolecular drug conjugates into patients with various diseases [6]. CPPs are capable of carrying a wide spectrum of cargo molecules, including many types of proteins, nucleic acids, peptide nucleic acids, cytotoxic drugs, inorganic particles and liposomes [4,6,16]. CPPs can deliver cargoes with sizes up to 200 nm in diameter [17]. Our laboratory has used arginine-rich CPPs to deliver proteins [18–26], DNAs [27–33], RNAs [34] and nanoparticles [35–39] into cells from various species. The internalization kinetics of CPPs is rapid, with a first-order rate constant of 0.007 sec⁻¹ [40]. CPPs are not toxic to most cells [30–32,35,37–41], and the safety of CPPs has been demonstrated by a metabolic analysis [42]. Recently, a detailed study further confirmed that CPPs are nontoxic in vitro and nonimmunogenic in vivo [43].
Quantum dots (QDs) are inorganic semiconductor nanocrystals first introduced in the 1980s [44]. QDs have a size-range of 1 to 100 nm and consist of a few hundred to a few thousand atoms [45]. QDs are attractive alternatives to fluorescent proteins due to their colloidal nature, wide excitation properties, and narrow, size-dependent and composition-tunable emission spectral ranges. QD advantages over traditional fluorescent proteins include photostability, high fluorescence quantum yields, resistance to photo-bleaching and chemical degradation, and high levels of brightness [45–47]. Accordingly, QDs are increasingly being used in biomedical imaging studies, as cellular labels, intracellular sensors, deep-tissue and tumor targeting, and imaging agents, and sensitizers for photodynamic therapy [48]. However, QDs do not readily enter cells, and aggregation often occurs before and after internalization [47,49]. To overcome these limitations, QDs have been surface-modified by either covalent [50–52] or noncovalent [35-39] linkages with CPPs. Though CPP-facilitated delivery of QDs reduces the nonspecific absorption and side effects [48], QDs are still susceptible to entrapment and sequestration by endosomes or lysosomes in cells.

Transduction enhancers and endosomolytic agents have been employed to improve CPP transduction efficiency and to overcome endosomal/lysosomal entrapment [38,53–55]. Most enhancers, such as pyrenebutyrate [33] and dimethyl sulfoxide (DMSO) [38,54], either increase the net hydrophobicity of CPPs or increase membrane permeability, while chloroquine is a lysosomotropic agent that prevents lysosomal trapping [55]. Insofar as endocytosis is one of the primary mechanisms of cellular uptake of CPPs, quick release from endocytic vesicles into the cytosol is essential to preserve biological activity of the cargoes [3,6–8]. Several lysosomotropic peptides, also called endosome-disruptive peptides or membrane destabilizing peptides, have been derived from viral and bacterial toxins [7]. These peptides trigger endosomal acidification that leads to cargo escape into the cytosol [56–58]. INF7 peptide, a glutamic acid-richened influenza virus hemagglutinin-2 (HA2) analogue, has been shown to be a particularly potent fusion peptide [59], as was used in the present study.

The aims of this study were to (1) create a chimeric IR9 CPP containing both INF7 fusion peptide and R9 (designated IR9); (2) evaluate the transduction of IR9 for cellular delivery of QDs and plasmid DNAs and (3) determine the mechanism of CPP-mediated uptake of QDs and DNAs in cells. To achieve these goals, we synthesized IR9 and examined the intracellular delivery of IR9, IR9/QD and IR9/DNA using live cell imaging and flow cytometry. To understand the relationship between transduction efficiency and IR9/cargo ratios, the charging state and electrostatic interactions of IR9/cargo complexes were characterized using a zeta-potential analyzer. To elucidate the uptake mechanisms of IR9 and IR9/cargo complexes, physical and pharmacological inhibitors were used to block specific endocytic pathways. Finally, the cytotoxicity of IR9 and IR9/cargo complexes was assessed.

**Materials and Methods**

**Cell Culture**

Human bronchoalveolar carcinoma A549 cells (American Type Culture Collection, Manassas, VA, USA; CCL-185) were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco, Invitrogen, Carlsbad, CA, USA) supplemented with 10% (v/v) bovine serum (Gibco) [35]. Living cells were determined by propidium iodide stain. Cells were washed with phosphate buffered saline (PBS) three times before and after each treatment. The culture medium was switched to RPMI 1640 medium supplemented with 1% serum during incubation with IR9-FITC, IR9/QD or IR9/DNA.

**QDs and Preparation of Peptides**

Carboxyl-functionalized CdSe/ZnS QDs eFluor 525NC (green fluorescent QD) and eFluor 625NC (red fluorescent QD; denoted as QDr) possess the maximal emission peak wavelengths of 525 and 625 nm, respectively (eBioscience, San Diego, CA, USA). IR9 peptide (GLFEAGFIEINGWEGMIDGWYGRRRRRRRR) of 92.9% purity was chemically synthesized (Genomics, Taipei, Taiwan). IR9-FITC peptide of 90.2% purity contained the fluorescein isothiocyanate (FITC) at the N-terminus (Genomics). The molecular masses of IR9 and IR9-FITC are 3996.6 and 4499.1 Dalton, respectively.

**Noncovalent QD Transduction**

In the protein transduction experiments, different amounts of IR9-FITC peptide (0, 1, 5, 10, 30 and 60 µM) were incubated with human A549 cells for 1 h, and cells were then analyzed with flow cytometry. Cells treated with PBS, FITC (Sigma-Aldrich, St. Louis, MO, USA) or a non-CPP (casein-FITC, Sigma-Aldrich) served as negative controls. In the kinetic study of transduction, 5 µM of IR9-FITC were added to cells for 0, 1, 5, 10, 30 and 60 min at 37°C. To determine subcellular colocalization of IR9-FITC, organelle-specific fluorescent trackers Hoechst 33342 (Invitrogen) and LysoTracker DND-99 (Invitrogen) were utilized to visualize nuclei and lysosomes, respectively, according to the manufacturer’s instructions. Cells were treated with 5 µM of IR9-FITC for 1 h and stained with both trackers [38].

For the transduction of noncovalent IR9/cargo complexes, 1, 5, 10, 30 and 60 µM of IR9 peptide were mixed with QDs at a molecular ratio of 60 at 37°C for 2 h. IR9/QD complexes were then incubated with the cells at 37°C for 1 h. To study transduction kinetics, cells were treated with IR9/QD complexes prepared at a molecular ratio of 60 for 0, 1, 5, 10, 30, 60 min, 12 h and 24 h at 37°C. In other experiments with high molecular ratios, cells were treated with IR9/QD complexes prepared at molecular ratios of 120 and 240 for 24 h followed by analysis with a confocal microscope or a flow cytometer. To test QD dissociation from CPPs, 5 µM of IR9-FITC was mixed with...
2.6 nM of QDr at 37°C for 2 h, and then incubated with cells for 24 h. Following incubation, IR9-FITC/QDr complexes were removed and cells were stained with Hoechst 33342, followed by observation using a confocal microscope. Lysosomal escape was conducted by adding 25 μM of chloroquine (Sigma-Aldrich) to cells previously treated with IR9/QD complexes for 24 h. The

Figure 1. Internalization of IR9 into human A549 cells. (A) Flow cytometric analysis of concentration-dependent entry of IR9 into human A549 cells. Cells were treated with FITC, casein-FITC, or 0, 1, 5, 10, 30 and 60 μM of IR9-FITC for 1 h, and the fluorescent intensity was analyzed using a Cytomics FC500 flow cytometer (Beckman Coulter). Data are presented as mean ± SD from 5 independent experiments in each treatment group. (B) Flow cytometric analysis of time course-dependent entry of IR9 into cells. Cells were treated with FITC, casein-FITC, or 5 μM of IR9-FITC for 0, 1, 5, 10, 30 and 60 min. The fluorescent intensity was analyzed using a flow cytometer. Significant differences of P<0.05 (*, a, b) and P<0.01 (**, aa, bb) are indicated. Data are presented as mean ± SD from 3 independent experiments in each treatment group. (C) Subcellular colocalization of IR9 after entry into cells. Cells were treated with either FITC and casein-FITC as controls or 5 μM of IR9-FITC as the experimental group for 1 h, and then stained with Hoechst 33342 and LysoTracker DND-99. Images were taken using a Leica confocal microscope system. Cell morphologies are shown as bright-field images. GFP, RFP and BFP channels revealed the distribution of FITC-labeled objects, lysosomes and nuclei, respectively. The merged images combined BFP, RFP and GFP channels at a magnification of 1,260 ×. Overlaps between peptides and organelle trackers exhibit yellow color in merged GFP and RFP images, while those between objects and nuclei show cyan color in merged GFP and BFP images. Scale bar is 25 μm.

doi:10.1371/journal.pone.0064205.g001
cells were then stained with LysoTracker DND-99 and Hoechst 33342.

To evaluate the role of endocytosis in complex transduction, physical and pharmacological endocytic modulators were used [38]. Cells were incubated at 4°C for 30 min to deplete energy required by all endocytic pathways; IR9-FITC, IR9/QD or IR9/DNA complexes were then incubated with the cells at 4°C. To analyze the role of macropinocytosis in complex transduction, cells were treated with 10 μM of cytochalasin D (CytD), 100 μM of 5-(N-ethyl-N-isopropyl)-amiloride (EIPA), 5 μg/ml of filipin or 10 μM of nocardazole (Sigma-Aldrich) for 1 h to block F-actin rearrangements, macropinocytosis, caveolae-dependent endocytosis or clathrin-dependent endocytosis, respectively. The cells were then treated with IR9-FITC, IR9/QD or IR9/DNA complexes and uptake determined.

DNA Delivery Mediated by IR9 and Functional Gene Assay

To prepare fluorescence-labeled DNAs, the pBlueScript-SK+ plasmid (Agilent Technologies, Santa Clara, CA, USA) was labeled with the LabelIT Cyanine 3 (Cy3) nucleic acid labeling kit (Mirus Bio, Madison, WI, USA) [27]. Cells were seeded at a

Figure 2. Noncovalent interactions between IR9 and QDs in vitro. (A) Gel retardation assay revealing stable interactions between IR9 and QDs. Different amounts of IR9 were mixed with QDs at molecular ratios of 0 (QD only), 15, 30, 60, 90 and 120. IR9/QD mixtures were subjected to electrophoresis on a 0.5% agarose gel. Fluorescence of QDs was visualized at 532 nm using a Typhoon Trio imager (GE Healthcare). (B) Relative shift of IR9/QD complexes formed at different IR9/QD ratios. Data are presented as mean ± SD from 6 independent experiments in each treatment group. doi:10.1371/journal.pone.0064205.g002
density of $1 \times 10^4$ per well of 96-well plates. Three μg of Cy3-labeled pBlueScript-SK+ plasmid DNA was incubated with IR9 at N/P ratios of 0 (Cy3-labeled DNA only), 1, 3, 6 and 9 in a final volume of 100 μL for 2 h at 37°C. The IR9/Cy3-labeled DNA complexes were added to cells in the 96-well plates, and the plates were incubated for 1 h at 37°C. The cells were washed three times with PBS to remove free IR9/Cy3-labeled DNA complexes, and then stained with Hoechst 33342.

In a functional gene assay, cells were treated with either 3 μg of the pEGFP-N1 plasmid DNA mixed with IR9 at N/P ratios of 0 (control), 3, 6, 9 or 12. These complexes were transferred to cells in each well for 1 h at 37°C. The cells were then washed three times with PBS. The cells were supplemented with 100 μL of 10% serum-containing medium and incubated at 37°C for 48 h, and then stained with Hoechst 33342 and observed using a confocal microscope [30,31].

Figure 3. Flow cytometric analysis of cellular internalization of IR9/QD complexes. (A) Concentration-dependent internalization of IR9/QD complexes into cells. Different amounts of IR9 (1, 5, 10, 30 and 60 μM) were mixed with QDs at a molecular ratio of 60. IR9/QD complexes were transferred onto cells and incubated for 1 h. The fluorescent intensity was analyzed using a flow cytometer. Cells treated with QDs alone served as a negative control. Data are presented as mean ± SD from 3 independent experiments in each treatment group. (B) Time-dependent internalization of IR9/QD complexes into cells. Five μM IR9 were mixed with QDs at a molecular ratio of 60 and then incubated with cells for 0 (negative control), 1, 5, 10, 30 and 60 min, as indicated. Data are presented as mean ± SD from 3 independent experiments in each treatment group. (C) Merged flow cytometric plots of cellular internalization of IR9/QD complexes. Cells were treated with IR9/QD complexes prepared at a molecular ratio of 120 at 37°C for 24 h (gray area). Results from the negative control are shown by the dotted line at the left, while results from the positive controls (5 μM of IR9-FITC) are shown by dashed line. (D) Cellular internalization comparison of IR9/QD complexes at different combined ratios. Cells were treated with different molecular ratios (60 and 120) of IR9/QD complexes for the indicated periods of time (12 and 24 h). Significant differences of $P<0.05$ (*, β) and $P<0.01$ (**, ββ) are indicated. Data are presented as mean ± SD from 3 independent experiments in each treatment group.

doi:10.1371/journal.pone.0064205.g003
Fluorescent and Confocal Microscopy

Fluorescent and bright-field images were recorded using a BD Pathway 435 bioimaging system (BD Biosciences, Franklin Lakes, NJ, USA) which includes both the fluorescent and confocal microscopic sets without a pinhole [38]. Excitation filters were at 377/50, 482/35 and 543/22 nm for blue, green and red fluorescence, respectively. Emission filters were at 435LP (long-pass), 536/40 and 593/40 nm for blue (BFP), green (GFP) and red fluorescent protein (RFP) channels, respectively. Confocal images were also obtained using the Leica confocal microscope system at a magnification of 1,260×. GFP, RFP and BFP channels revealed the distribution of IR9-FITC, QDr and nuclei, respectively. Overlaps between peptides and QDr were yellow in merged GFP and RFP images. (C) Subcellular colocalization of IR9-delivered QDs. Cells were treated with IR9/QD complexes prepared at a molecular ratio of 120 for 24 h in the absence or presence of 25 μM chloroquine. Cells were stained with LysoTracker DND-99 and Hoechst 33342, and images were then observed using a BD Pathway System at a magnification of 600×. GFP, RFP and BFP channels displayed the distribution of QDs, lysosomes and nuclei, respectively. Overlaps between QDs and lysosomes were yellow/orange color in merged GFP and RFP images.

doi:10.1371/journal.pone.0064205.g004

Flow Cytometric Analysis

Cells were seeded at a density of 2.5 × 10⁵ per well of 24-well plates. Cells in the control and experimental groups treated with IR9-FITC or IR9/cargo complexes were harvested and counted using a Cytomics FC500 flow cytometer (Beckman Coulter, Fullerton, CA, USA) with a FL1 filter for GFP detection [19,24]. Data were analyzed using CXP software (Beckman Coulter).

Zeta-potential Analysis

IR9 (12.4 μM), QD (100 nM), pEGFP-N1 plasmid DNA (7 μg), IR9/QD complexes formed at molecular ratios of 60, 120 and 240, and IR9/DNA complexes formed at N/P ratios of 9 and 12 were prepared in double deionized water. Each solution was temperature-equilibrated at 25°C for 120 sec in a zeta cell. Zeta-potentials of samples were measured using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) and analyzed using Zetasizer software 6.30 (Malvern) [39]. The correlation coefficient analysis between zeta-potential and protein transduction efficiency was plotted using SigmaPlot software (Systat, Chicago, IL, USA).
Cytotoxicity Measurement

Cells were treated with 1, 5, 10, 30 and 60 μM of IR9-FITC, IR9, IR9/QD or IR9-FITC/QD complexes prepared at CPP/probe ratios of 60:1, 120:1 and 240:1 for 24 h at 37°C. To measure the transduction of IR9/DNA complexes, cells were treated with IR9/pEGFP-N1 complexes prepared at N/P ratios of 0 (DNA only), 1, 3, 6, 9 and 12 for 24 h at 37°C. Cells without any treatment served as a negative control, while cells treated with 100% DMSO served as a positive control [60]. Cell viability was determined using the 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) assay [31].

Statistical Analysis

Results are expressed as mean ± standard deviation (SD). Mean values and SDs were calculated from at least three independent experiments of triplicates per treatment group. Comparisons between the control and treated groups were performed by the Student’s t-test using levels of statistical significance of $P < 0.05$ (*, α, β) and 0.01 (**, αα, ββ), as indicated.

Results

To determine the kinetics of protein transduction of the novel IR9 peptide, human A549 cells were treated with FITC, casein-FITC, or various amounts of IR9-FITC peptide and analyzed by flow cytometry. Cellular internalization of IR9-FITC peptide was concentration-dependent (Fig. 1A). The kinetic experiment showed that internalization of IR9-FITC is time-dependent, entering into cells within 1 min and reaching a stationary phase at 60 min (Fig. 1B). The IR9-FITC was distributed evenly throughout the cytosol. Merged images indicated that IR9-FITC is colocated with lysosomes (Fig. 1C). These results demonstrate that IR9 possesses protein transduction ability.

Noncovalent interactions between IR9 and QDs were confirmed in an agarose-based gel retardation assay (Fig. 2A). Semi-quantitative analysis revealed ratio-dependent interactions of IR9/QD complexes reaching a plateau at a molecular ratio of 60 (Fig. 2B). Accordingly, this ratio was used in subsequent experiments.

To study IR9-dependent cellular internalization, cells were treated with IR9/QD complexes containing different amounts of IR9 but a fixed ratio of 60 with QDs. The transduction of IR9 was concentration-dependent (Fig. 3A), and intracellular accumulation...
of IR9/QD complexes could be detected within 1 min (Fig. 3B). We noted stronger fluorescence at a molecular ratio of 60 of IR9/QD complexes in 24 h compared to that in 12 h (Fig. 3C and D). A much larger fraction of the cells internalized IR9/QD complexes at a molecular ratio of 120 compared to that at a ratio of 60 (Fig. 3C and D). These data suggest that IR9 not only can interact with QDs to form stable IR9/QD complexes (Fig. 2), but also can deliver QDs into cells (Fig. 3).

To reveal the subcellular localization of IR9-delivered QDs, cells were treated with QDs only or IR9/QD complexes at various combination ratios, and then stained with a nucleus-specific fluorescent marker Hoechst 33342. The IR9-delivered QDs were evenly distributed in the cytosol (Fig. 4A). To address whether CPPs and cargos dissociate after cellular internalization, cells were treated with IR9-FITC/QDr complexes, and then stained with Hoechst 33342. The merged image showed that QDs were largely colocalized with IR9 within cells (Fig. 4B). This indicates that QDs remain associated with IR9 following cellular entry. Additionally, lysosomal escape was affected using the lysosomotropic agent chloroquine. The cells were then stained with nucleus- and lysosome-specific fluorescent markers (Hoechst 33342 and Lyso-Tracker DND-99, respectively). The QDs initially colocalized with lysosomes, and chloroquine facilitated cytoplasmic distribution of IR9-delivered QDs (Fig. 4C). Green puncta were observed in the cells treated with IR9/QD complexes, but no green puncta were seen in the cells treated with IR9/QD complexes and chloroquine (Fig. 4C). These results suggest that intracellular delivery of IR9/QD complexes may involve an endocytic pathway, and chloroquine promotes lysosomal escape.

To assess whether IR9 can deliver genes into cells, we switched QD cargos to plasmid DNAs. A gel retardation assay was conducted with IR9 and the pEGFP-N1 plasmid DNA. Results indicated that IR9 noncovalently associates with DNAs to form stable IR9/DNA complexes (Fig. 5A). DNA mobility decreased as the amount of IR9 increased (Fig. 5B). Thus, IR9 interacts with DNAs to form stable IR9/DNA complexes in vitro.

To determine whether DNA plasmids are delivered by IR9 into cells, A549 cells were treated with IR9/Cy3-labeled pBlueScript-SK+ plasmid DNA complexes at various N/P ratios, stained with Hoechst 33342, and then observed using a fluorescent microscope. No signal was detected in cells treated with Cy3-labeled DNA alone (Fig. 6A). In contrast, red fluorescence was observed in cells treated with IR9/Cy3-labeled DNA complexes when N/P was >1. This indicates that IR9 can transport DNA into cells. In the functional gene assay, cells were treated with IR9/pEGFP-N1 complexes at different N/P ratios and stained with Hoechst 33342. No signal was detected in cells treated with the pEGFP-N1 plasmid DNA encoding an EGFP reporter gene (Fig. 6B). In contrast, green fluorescence was observed in cells treated with IR9/DNA complexes when N/P was >6, indicating that plasmid DNAs delivered by IR9 can be actively expressed by cells.

To understand the contribution of N/P ratio in transduction efficiencies of IR9/cargo complexes (i.e., Fig. 2 versus Fig. 3D and 4; and Fig. 5 versus Fig. 6), the charge state of IR9, cargo and IR9/cargo complexes were characterized using a zeta-potential analyzer. Zeta values of carboxyl-functionalized QDs and arginine-rich IR9 were $-25.1 \pm 2.2$ mV and $32.8 \pm 1.3$ mV, respectively (Fig. 7A). The surface charge of IR9/QD complexes formed at a molecular ratio of 60 was near neutral ($3.7 \pm 1.2$ mV).
However, zeta values of IR9/QD complexes were dramatically elevated at molecular ratios above 60 (Fig. 7B). This relationship was also observed with IR9/DNA complexes. While plasmid DNA has a zeta-potential of $-37.6 \pm 1.9$ mV, the zeta value of IR9/DNA complexes was $4.92 \pm 0.5$ mV at an N/P ratio of 9 and $32.2 \pm 0.7$ mV at an N/P ratio of 12 (Fig. 7C). A logarithmic curve was plotted with zeta potential against protein transduction efficiency to generate an equation of $y = 41.676 \ln(x) - 35.16$ with an R-squared value of 0.9737 (Fig. 7D). The correlation coefficient analysis demonstrated a high correlation between the zeta-potential and protein transduction efficiency of CPP/DNA complexes. Thus, in addition to gel shift ability, the electrostatic interactions of CPP/cargo complexes can be a predictor of transduction efficiency within the charge range tested.

We used physical and pharmacological inhibitors to elucidate mechanisms of cellular internalization of IR9 and its associated cargoes. Cells were treated with PBS (as a negative control), IR9-FITC, IR9/QD or IR9/DNA complexes in the absence or presence of endocytic inhibitors, followed by flow cytometric analysis. We found that cellular uptake of IR9-FITC was sensitive to treatments of 4°C, CytD and EIPA (Fig. 8A). Cellular internalization of IR9/QD complexes was inhibited by treatments of 4°C, CytD, EIPA and nocodazole (Fig. 8B). Cellular entry of IR9/DNA complexes was sensitive to treatments of 4°C, CytD, EIPA, filipin and nocodazole (Fig. 8C and D). These results indicate that the classical energy-dependent endocytosis may be one of the main routes for cellular internalization of IR9 and IR9/cargo complexes.

The MTT assay was performed to determine the effect of IR9-mediated cargo delivery on cell viability. Cells were treated with IR9-FITC, IR9, IR9/QD or IR9-DNA complexes for 24 h. IR9 alone and IR9/QD complexes were not cytotoxic at concentrations below 30 μM, while IR9/QD complexes above 5 μM at a molecular ratio of 240 were toxic (Fig. 9A). IR9/DNA complexes showed no cytotoxicity when N/P was below 12, corresponding to concentrations below 20.1 μM (Fig. 9B).

**Discussion**

In this study, we introduce and characterize a novel cell-penetrating peptide without labor intensive production of proteins from prokaryotes. IR9 is a chimeric molecule derived from fusion of synthetic nona-arginine and the fusogenic peptide INF7. IR9 can noncovalently interact with QDs and DNAs to form stable complexes and deliver both into human A549 cells. A high correlation is noted between zeta-potential and protein transduction efficiency of CPP/DNA complexes. Electrostatic interactions of IR9/cargo complexes with the plasma membrane play an important role in cellular internalization. Endocytosis may be one of the main routes for cellular uptake of IR9 and IR9/cargo complexes. Neither IR9 nor IR9/cargo complexes are cytotoxic at low concentrations. These properties indicate that IR9 may be a useful tool in the study of biological processes, including gene expression, as well as a delivery vector in biomedical applications.
Poor intracellular trafficking and endosomal release are major factors that reduce efficiency of CPP protein transduction mediated by endocytic pathways [3,6,8,56]; endosomal entrapment can lead to enzymatic degradation of CPPs and their cargoes. Entrapment in endosomes or macropinosomes can be overcome by incorporating HA2 and INF7 peptides into CPPs to induce perturbation of vesicle membranes [57,61–64]. We recently reported that the endosomolytic HA2 tag increases cellular uptake, accelerates endosomal escape, and promotes the even cytosolic distribution of endocytosed CPP-containing RFPs in human A549 cells [65]. The working concentrations of the cumbersome bacteria-produced R9-HA2-mCherry [65] and synthetic IR9-FITC were 30 and 5 μM, respectively. The relative transduction efficiency of 5 μM of IR9-FITC was much higher than that of 5 μM of R9-HA2-mCherry, whereas similar transduction efficiencies were noticed at high concentrations (both 30 and 60 μM) of R9-HA2-mCherry and IR9-FITC. Less cytotoxicity was detected with 30 μM of R9-HA2-mCherry; however, the same concentration of IR9 reduced cell viability.

Membrane potential plays a critical role in the internalization of arginine-rich CPPs into cells [66,67]. We hypothesized that the charge state of IR9/cargo complexes can influence the efficiency of CPP-mediated cellular internalization. Protein transduction of CPP-mediated cargo delivery can be envisioned as a three-step process: first, binding to cellular membranes; second, penetration into cells; and third, release into cytoplasm or specific organelles [6,58]. The first step of cellular uptake is initiated by electrostatic interactions between CPP/cargo complexes and negatively charged plasma membranes [58]. For instance, surface charge is a major determinant of how gold nanoparticles impact cellular processes, such as cell morphology, mitochondrial function, intracellular calcium levels and cytotoxicity [68]. Both positively and negatively charged gold particles are cytotoxic, with the negative ones being more toxic. Recently, electropositive zeta-potentials of nanodiamond particles were found to vary greatly depending on nanoparticle size, methods of production and treatment, surface structure and other properties [39,69]. In our gel retardation assay, IR9/QD complexes attained a plateau of complex formation at a molecular ratio of 60 (Fig. 2), although higher transduction efficiencies were attained with higher molecular ratios, such as 120 (Fig. 3D and 4A). The transduction efficiency of IR9/cargo complexes correlated well with the magnitude of electropositive zeta-potentials of IR9/cargo complexes (Fig. 7). Electropositivity at or above 25 mV can be taken as an arbitrary value separating low-charged surfaces from highly-charged surfaces that contributes to suspension stability in colloidal systems [70]. Hence, this electrostatic property that governs CPP/cargo complex interactions with the negatively charged plasma membranes appears to be the key factor in determining transduction efficiency, rather than simple complex formation per se (as indicated by gel shift assay).

Though the understanding of cellular internalization of CPP/cargo complexes is still incompletely understood, the general belief is that most CPPs utilize two or multiple pathways for cellular entry [3–8]. Two major routes for cellular uptake of CPPs are the endocytic and nonendocytic pathways. Classical endocytosis is an energy-dependent pathway and includes both phagocytosis and pinocytosis [71,72]. The nonendocytic route (also called direct membrane translocation, direct penetration, or pore-opening mechanism) is a rapid and energy-independent pathway [3,73].

Figure 8. Mechanisms of cellular internalization of IR9 and IR9/cargo complexes. (A) Effect of inhibitors on cellular uptake of IR9-FITC. Cells were treated with PBS (negative control) or IR9-FITC in the absence or presence of the endocytic inhibitors CytD, EIPA, filipin, nocodazole and treatment of 4°C. After treatment for 1 h, the cells were analyzed by flow cytometry. (B) Effect of inhibitors on the cellular uptake of IR9/QD complexes. Cells were treated with PBS (negative control) or IR9/QD complexes in the absence or presence of endocytic inhibitors. (C) Cellular uptake of IR9/DNA complexes without or with inhibitors. Scale bar is 75 μm. (D) Effect of inhibitors on the cellular uptake of IR9/DNA complexes. Cells were treated with PBS (negative control), DNAs alone or IR9/DNA complexes in the absence or presence of endocytic inhibitors. Significant differences of P<0.05 (*) and P<0.01 (**) are indicated. Data are presented as mean ± SD from 3 independent experiments in each treatment group.
doi:10.1371/journal.pone.0064205.g008
Antennapedia, R9 and Tat have been reported to simultaneously use at least three endocytic pathways: macropinocytosis, clathrin-mediated endocytosis and caveolae/lipid-raft-mediated endocytosis [74]. In this study, endocytosis was found to be one of the main routes for cellular uptake of IR9 and IR9/cargo complexes (Fig. 8).

The pathways involved in the internalization of QDs depend on their conjugated peptides or carriers [75–77]. CPP properties, CPP concentration, cargo characteristics, CPP/cargo complexing method, duration of transduction, serum concentration and composition of cell membrane have all been reported to influence cellular uptake efficiency and pathways of CPPs [56,74,78–81].

Conclusions

A novel CPP, IR9, noncovalently interacts with QDs or DNAs to form stable complexes that are able to deliver into human A549 cells. Electrostatic interactions of IR9/cargo complexes with...
cellular membranes play a key role in cellular internalization. IR9 and IR9/cargo complexes may enter cells by endocytosis. IR9 includes the NLF fusogenic domain which promotes the release of IR9/cargo complexes from endosomes. IR9 is relatively nontoxic and may be an excellent carrier of therapeutic cargoes in biomedical applications.

Acknowledgments

We thank Chia-Liang Cheng (Department of Physics, National Dong Hwa University, Taiwan) for performing the zeta-potential measurements, and We thank Chia-Liang Cheng (Department of Physics, National Dong Hwa University, Taiwan) for performing the zeta-potential measurements, and may be an excellent carrier of therapeutic cargoes in biomedical applications.

References


